New and larger framework contract with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) replaces previous agreement and provides for up to 8 million doses of ...

Following achievement of the Return Cap, a royalty-only tail period will commence, which entitles HCRx to a predefined, reduced share of royalties not to exceed $14.9 million per year; the tail period ...

Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third ...

Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue ...

The presentation will provide two-year follow-up data from the landmark BOOSTB4 Phase I/II clinical study. Notably, the results demonstrate that more than 50% of the treated patients experienced zero ...

The live webcast of the ‘Fireside Chat’ will be available here. The replay will also be available at the same link or our website ( here) for 90 days post the event.

In February 2025, Nxera Pharma announced that it had entered a license, supply and commercialization agreement with Holling Bio-Pharma Corp. for daridorexant in Taiwan.

Corbus intends to use the net proceeds of the offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes. Jefferies LLC is acting as the ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

BEIJING, Oct. 30, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m.

Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET. SARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage med ...